Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100184033 | 10018403 | 3 | F | 20131017 | 20140318 | 20140930 | EXP | US-ALEXION PHARMACEUTICALS INC.-A201202984 | ALEXION | 0.00 | Y | 0.00000 | 20140930 | N | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100184033 | 10018403 | 1 | PS | SOLIRIS | ECULIZUMAB | 1 | INTRAVENOUS | 900 MG, Q2W | D | 125166 | 900 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | |||||
| 100184033 | 10018403 | 2 | SS | SOLIRIS | ECULIZUMAB | 1 | INTRAVENOUS | 900 MG, Q2W | D | 125166 | 900 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | |||||
| 100184033 | 10018403 | 3 | C | CARVEDILOL. | CARVEDILOL | 1 | UNKNOWN | 12.5 MG, BID | D | 0 | 12.5 | MG | BID | ||||||
| 100184033 | 10018403 | 4 | C | LISINOPRIL. | LISINOPRIL | 1 | UNKNOWN | 10 MG, QD | D | 0 | 10 | MG | QD | ||||||
| 100184033 | 10018403 | 5 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | UNKNOWN | 12.5 MG, QD | D | 0 | 12.5 | MG | QD | ||||||
| 100184033 | 10018403 | 6 | C | VITAMIN B12 | CYANOCOBALAMIN | 1 | UNKNOWN | UNK | D | 0 | |||||||||
| 100184033 | 10018403 | 7 | C | FOLIC ACID WITH VITAMIN C AND IRON | 2 | UNKNOWN | 1 DF, QD | D | 0 | 1 | DF | CAPSULE | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 100184033 | 10018403 | 1 | Paroxysmal nocturnal haemoglobinuria |
| 100184033 | 10018403 | 3 | Product used for unknown indication |
| 100184033 | 10018403 | 4 | Product used for unknown indication |
| 100184033 | 10018403 | 5 | Product used for unknown indication |
| 100184033 | 10018403 | 6 | Product used for unknown indication |
| 100184033 | 10018403 | 7 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 100184033 | 10018403 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 100184033 | 10018403 | Aplastic anaemia | |
| 100184033 | 10018403 | Blood iron decreased | |
| 100184033 | 10018403 | Gout | |
| 100184033 | 10018403 | Haemoglobin decreased | |
| 100184033 | 10018403 | Malaise | |
| 100184033 | 10018403 | Myelodysplastic syndrome | |
| 100184033 | 10018403 | Platelet count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 100184033 | 10018403 | 1 | 20111114 | 0 | ||
| 100184033 | 10018403 | 2 | 20130826 | 0 |